Eliminate development bottlenecks caused by vendor complexity with integrated drug development services.
What is Quotient Sciences Translational Pharmaceutics®?
The Quotient Sciences Translational Pharmaceutics® platform is an integrated approach to drug development that combines formulation development, drug product manufacturing, and clinical testing into a single, seamless program.
- Redefines Drug Development
For nearly two decades and more than 500 drug programs, we’ve pioneered the integration of CRDMO services. We merge operational efficiencies, scientific rigor, and clinical insights into a single program of work, delivered under a single project manager and organization.
- Uses Efficiency to Save Time
Close integration between drug product manufacturing and clinical testing enables better decision-making while reducing time and waste. Our approach lets us manufacture and release drug products in less than seven days, then test and optimize in our clinics.
- Applies Science-Led Insight
We've developed, tested, and manufactured a range of drug product formulations, both simple and complex. Our expertise across different dosage forms and therapeutics lets us anticipate and overcome challenges to create a personalized path for your molecule.
Reach POC 8-12 months sooner through an integrated partner across formulation, manufacture & clinic
Translational Pharmaceutics® is one integrated solution to reduce vendor friction, tackle complex molecules, and increase development speed and agility to reach key milestones more efficiently. Sponsors that choose Translational Pharmaceutics® can reach proof-of-concept clinical studies 8-12 months sooner with a lower capital burn.
Quotient Sciences is an integrated CRDMO partner that puts you in control of your drug program, with trusted insight you need to navigate the complexity of early development.
Measurable, Trusted Results
Eliminates multi-vendor friction
to simplify your drug development supply chain
Better, more actionable decisions
that can be based on emerging human clinical data
Timeline acceleration
to reach proof-of-concept studies 8-12 months sooner
Provides flexibility
to adjust formulation composition within a study
$8-30 million savings
in runway costs by reaching proof-of-concept sooner
Conserves API
for high-value drug substance
Translational Pharmaceutics® helps you develop your drug—from first-in-human studies to managing your ongoing product lifecycle
- Translational Pharmaceutics® for accelerating first-in-human, Phase I clinical testing
Reach a pivotal milestone with our phase-specific drug product to test the safety and tolerability of your drug.
- Translational Pharmaceutics® for drug product optimization in Phase Ib/IIa clinical studies
Simplify reformulation after Phase I and beyond to manage product lifecycle, ensure continued innovation, and meet trial success.
- Translational Pharmaceutics® for more efficient, integrated human ADME studies
Whether for New Drug Applications (NDA) or in parallel with Phase II / proof-of-concept studies, we integrate services to ensure better ADME study outcomes.
Insight from our customers about the advantages of Translational Pharmaceutics®
Meet Quotient Sciences Translational Pharmaceutics® Experts
Dr. Andrew Lewis
Chief Scientific Officer
Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams...
About AndrewJohn McDermott
VP, Scientific Consulting
John McDermott leads Quotient Sciences' global drug development consulting, research fellows, modeling & simulation, and clien...
About JohnDr. Vanessa Zann
VP, Scientific Consulting, Translational Pharmaceutics & Clinical Pharmacology - USA
Dr. Vanessa Zann has over twenty-five years industry experience providing expert biopharmaceutic support to drug discovery, early ...
About VanessaDr. Andrew Parker
Executive Drug Development Consultant
Dr. Andrew Parker has over two decades of experience in the pharmaceutical industry, spanning from preclinical development, throug...
About Andrew